zura bio is a clinical-stage biotechnology company advancing zb-168 in alopecia areata and other inflammatory diseases. zb-168 is an anti il7rα inhibitor that has the potential to impact diseases driven by il7 and tslp biological pathways. zura bio aims to develop a portfolio of therapeutic indications for zb-168, and is focused on demonstrating its efficacy, safety, dosing convenience and mechanism of action, initially in alopecia areata. this will build on phase 1b data in type 1 diabetes demonstrating a favourable safety profile and strong biological rationale. zura bio is headquartered in london, uk with team members in the uk and usa.